Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open-label Phase 2 Study of KRN23 in Young Children with X-linked Hypophosphatemia
2018-001983-49Phase 2
- Sponsor
- Ultragenyx Pharmaceutical Inc.
- Start
- Oct 2019
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of burosumab in X-linked hypophosphataemia (XLH) and Hereditary Hypophosphatemic Rickets (XLH), sponsored by Ultragenyx Pharmaceutical Inc. Primary endpoints: Safety, Pharmacodynamics and 1 more.
02
Drugs
burosumab
03
Conditions
X-linked hypophosphataemia (XLH)Hereditary Hypophosphatemic Rickets (XLH)
Beyond the preview
Go deeper on 2018-001983-49.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-001983-49.